con il contributo non condizionante di:
SESSION I: INTERMEDIATE RISK AML
Chairpersons: A. Fiorentini (Ancona), A. Venditti (Roma)
Should intermediate risk fit patients undergo allo HSCT in CR1? YES
S. Piemontese (Milano)Should intermediate risk fit patients undergo allo HSCT in CR1? NO
F. Buccisano (Roma)Should intermediate risk AML patients receive gemtuzumab? YES
M.P. Martelli (Perugia)Should intermediate risk AML patients receive gemtuzumab? NO
L. Brunetti (Ancona)SESSION II: MAINTENANCE THERAPY IN AML
Chairpersons: D. Capelli (Ancona), G. Visani (Pesaro)
Should AML patients in CR1 unfit for HSCT receive maintenance? YES
P. Minetto (Genova)Should AML patients in CR1 unfit for HSCT receive maintenance? NO
G. Marconi (Meldola-FC)Should high risk AML patients undergo maintenance following HSCT? YES
G. Battipaglia (Napoli)Should high risk AML patients undergo maintenance following HSCT? NO
N. Santoro (Pescara)SESSION III: HIGH-RISK AML IN OLDER PATIENTS
Chairpersons: G. Mancini (Ancona), A. Olivieri (Ancona)
What is the best induction treatment? CPX-351
P. Minetto (Genova)What is the best induction treatment? FLAI/FLAG
C. Papayannidis (Bologna)What is the best induction treatment? HMA+VEN
C. Vetro (Catania)Does conditioning intensity matter? YES
A. Pierini (Perugia)Does conditioning intensity matter? NO
F. Saraceni (Ancona)SESSIONE IV: GVHD PROPHYLAXIS FOR ALLO-HSCT IN AML
Chairpersons: P. Galieni (Ascoli Piceno), I. Scortechini (Ancona)